Neurological
Refine search
Pharmaceutical
German pharma Boehringer Ingelheim has handed full commercial and marketing rights for digital schizophrenia therapy CT-155 to US-based Click Therapeutics, reshaping a partnership first struck in 2020. 10 April 2026
Pharmaceutical
USA-based neurodegenerative disorders specialist Annovis Bio today revealed that it has secured financing to support the development of its investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. 10 April 2026
Biotechnology
Privately-held Alloy Therapeutics, a biotech ecosystem company promising to democratize access to new drug discovery technologies, has announced a collaboration and license agreement with US biotech major Biogen. 8 April 2026
Biotechnology
German drug developer Evotec reported fourth-quarter 2025 revenue of $293 million, up 14%, and adjusted EBITDA of $67 million, up 103%, driven largely by a license payment linked to the sale of its Toulouse biologics site to Sandoz. 8 April 2026
Biotechnology
Shares of Swiss biopharma AC Immune were up nearly 7%, at $2.88 by mid-morning, after it revealed an amendment to its collaboration with US pharma giant Eli Lilly. 7 April 2026
Biotechnology
US drug developer Denali Therapeutics on Friday revealed it has received notification from Japan’s Takeda of its decision to terminate the collaboration agreement between the two companies to co-develop and co-commercialize DNL593 (PTV:PGRN). 7 April 2026
Pharmaceutical
Independent French pharma major Servier announced that the UK’s National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending Voranigo (vorasidenib). 3 April 2026
Pharmaceutical
Precision oncology start-up Fore Biotherapeutics announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to plixorafenib for the treatment of adult patients with BRAF V600E-mutated high-grade glioma (HGG). 2 April 2026
Pharmaceutical
US biopharma Axsome Therapeutics announced that it has entered into an asset purchase agreement to obtain exclusive global rights to TAK-063 (balipodect), a novel, oral, potent, and selective phosphodiesterase 10A (PDE10A) inhibitor from Japan’s Takeda. 2 April 2026
Pharmaceutical
The US Centers for Medicare & Medicaid Services (CMS), through the CMS Innovation Center, announced that organizations participating in certain Innovation Center models may begin offering a new Substance Access Beneficiary Engagement Incentive (BEI) starting April 1, 2026. 2 April 2026
Biotechnology
Cyclerion Therapeutics’ shares more than doubled in Wednesday’s pre-market trade, rallying nearly 200% to $1.55 after the company announced a merger deal with privately-held Korsana Biosciences 1 April 2026
Pharmaceutical
Shares of US clinical-stage drug developer Centessa Pharmaceuticals leapt 44% to $39.72 on the news that it has reached a definitive agreement for US pharma major Eli Lilly to acquire the company. 1 April 2026
Pharmaceutical
Swiss neurotech firm MindMaze Therapeutics and US provider Vibra Healthcare have reported real-world evidence suggesting technology-enabled, high-dose therapy can improve recovery outcomes for stroke patients in inpatient rehabilitation. 31 March 2026
Pharmaceutical
As Parkinson’s disease (PD) awareness month approaches this April, analysis of the global drug landscape reveals an evolving research focus in PD. 30 March 2026
Biotechnology
Swiss biotech Idorsia’s share rose 5.7% to 3.24 francs in early trading, after it announced positive top-line results from its Phase II dose-finding study evaluating 10mg, 25mg and 50mg doses of daridorexant – the company’s dual orexin receptor antagonist (DORA) – in pediatric patients aged 10 to < 18 years with insomnia disorder. 30 March 2026
Biotechnology
San Diego, USA-based late-stage biotech ADARx Pharmaceuticals announced the appointment of Ryan Fisk as chief financial officer and chief business officer. In this role, he will be responsible for leading finance, strategy, corporate development and investor relations for the company. 28 March 2026
Pharmaceutical
Japan’s Otsuka Pharmaceutical is to buy US firm Transcend Therapeutics for $700 million upfront and up to $525 million in milestones, for a total potential consideration of $1.225 billion. 27 March 2026
Pharmaceutical
The US Food and Drug Administration is requiring new label warnings for widely used Parkinson’s therapies combining levodopa and carbidopa, citing a risk of vitamin B6 deficiency that may trigger seizures. 26 March 2026
Pharmaceutical
Japan still matters to specialty drug makers for a simple reason: it has a large and fast-aging patient population, broad public insurance and one of the world’s biggest pharmaceutical markets. That combination keeps the country high on launch plans for companies with products in cancer, neurology, ophthalmology and other diseases linked to older age. 26 March 2026
Pharmaceutical
The US Food and Drug Administration (FDA) yesterday approved Denali Therapeutics’ Avlayah (tividenofusp alfa-eknm) to treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II). 26 March 2026
Pharmaceutical
German pharma Boehringer Ingelheim has handed full commercial and marketing rights for digital schizophrenia therapy CT-155 to US-based Click Therapeutics, reshaping a partnership first struck in 2020. 10 April 2026
Pharmaceutical
USA-based neurodegenerative disorders specialist Annovis Bio today revealed that it has secured financing to support the development of its investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. 10 April 2026
Biotechnology
Privately-held Alloy Therapeutics, a biotech ecosystem company promising to democratize access to new drug discovery technologies, has announced a collaboration and license agreement with US biotech major Biogen. 8 April 2026
Biotechnology
German drug developer Evotec reported fourth-quarter 2025 revenue of $293 million, up 14%, and adjusted EBITDA of $67 million, up 103%, driven largely by a license payment linked to the sale of its Toulouse biologics site to Sandoz. 8 April 2026
Biotechnology
Shares of Swiss biopharma AC Immune were up nearly 7%, at $2.88 by mid-morning, after it revealed an amendment to its collaboration with US pharma giant Eli Lilly. 7 April 2026
Biotechnology
US drug developer Denali Therapeutics on Friday revealed it has received notification from Japan’s Takeda of its decision to terminate the collaboration agreement between the two companies to co-develop and co-commercialize DNL593 (PTV:PGRN). 7 April 2026
Pharmaceutical
Independent French pharma major Servier announced that the UK’s National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending Voranigo (vorasidenib). 3 April 2026
Pharmaceutical
Precision oncology start-up Fore Biotherapeutics announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation (BTD) to plixorafenib for the treatment of adult patients with BRAF V600E-mutated high-grade glioma (HGG). 2 April 2026
Pharmaceutical
US biopharma Axsome Therapeutics announced that it has entered into an asset purchase agreement to obtain exclusive global rights to TAK-063 (balipodect), a novel, oral, potent, and selective phosphodiesterase 10A (PDE10A) inhibitor from Japan’s Takeda. 2 April 2026
Pharmaceutical
The US Centers for Medicare & Medicaid Services (CMS), through the CMS Innovation Center, announced that organizations participating in certain Innovation Center models may begin offering a new Substance Access Beneficiary Engagement Incentive (BEI) starting April 1, 2026. 2 April 2026
Biotechnology
Cyclerion Therapeutics’ shares more than doubled in Wednesday’s pre-market trade, rallying nearly 200% to $1.55 after the company announced a merger deal with privately-held Korsana Biosciences 1 April 2026
Pharmaceutical
Shares of US clinical-stage drug developer Centessa Pharmaceuticals leapt 44% to $39.72 on the news that it has reached a definitive agreement for US pharma major Eli Lilly to acquire the company. 1 April 2026
Pharmaceutical
Swiss neurotech firm MindMaze Therapeutics and US provider Vibra Healthcare have reported real-world evidence suggesting technology-enabled, high-dose therapy can improve recovery outcomes for stroke patients in inpatient rehabilitation. 31 March 2026
Pharmaceutical
As Parkinson’s disease (PD) awareness month approaches this April, analysis of the global drug landscape reveals an evolving research focus in PD. 30 March 2026
Biotechnology
Swiss biotech Idorsia’s share rose 5.7% to 3.24 francs in early trading, after it announced positive top-line results from its Phase II dose-finding study evaluating 10mg, 25mg and 50mg doses of daridorexant – the company’s dual orexin receptor antagonist (DORA) – in pediatric patients aged 10 to < 18 years with insomnia disorder. 30 March 2026
Biotechnology
San Diego, USA-based late-stage biotech ADARx Pharmaceuticals announced the appointment of Ryan Fisk as chief financial officer and chief business officer. In this role, he will be responsible for leading finance, strategy, corporate development and investor relations for the company. 28 March 2026
Pharmaceutical
Japan’s Otsuka Pharmaceutical is to buy US firm Transcend Therapeutics for $700 million upfront and up to $525 million in milestones, for a total potential consideration of $1.225 billion. 27 March 2026
Pharmaceutical
The US Food and Drug Administration is requiring new label warnings for widely used Parkinson’s therapies combining levodopa and carbidopa, citing a risk of vitamin B6 deficiency that may trigger seizures. 26 March 2026
Pharmaceutical
Japan still matters to specialty drug makers for a simple reason: it has a large and fast-aging patient population, broad public insurance and one of the world’s biggest pharmaceutical markets. That combination keeps the country high on launch plans for companies with products in cancer, neurology, ophthalmology and other diseases linked to older age. 26 March 2026
Pharmaceutical
The US Food and Drug Administration (FDA) yesterday approved Denali Therapeutics’ Avlayah (tividenofusp alfa-eknm) to treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II). 26 March 2026
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze